Kornimate/medical-research-clean huggingface dataset:
the mechanism of endogenous nociceptin/orphanin fq(n/ofq) and β1-adrenoceptor autoantibody in promoting ischemic arrhythmia in rats

Conditions: Acute Myocardial Ischemia

Summary: in the early stage of ischemic arrhythmia, endogenous n/ofq regulates the expression of β 1-aa, mediates the internalization of β 1-ar by pkc/erk1/2, and thus affects the occurrence of arrhythmia. further clarify the regulatory mechanism of n/ofq on β 1-ar internalization and arrhythmia, providing experimental basis for drug development and target exploration of clinical ischemic arrhythmia; to observe the relationship between endogenous n/ofq and β 1-aa in serum of patients with coronary heart disease and diabetes.

this project mainly involves animal experiments and cell experiments. the part of clinical trials involved is the extraction of autoantibodies to β 1-adrenoceptor (β 1-aa) from the serum of patients with coronary heart disease and diabetes. the purified antibodies are intended to be used as agonists to rapidly increase the concentration of β 1-aa in the body of animals and the environment of cells in a short time, observe the impact of the antibodies on animals and cells, and further clarify that β 1-aa affects the internalization of β 1-ar through pkc/erk1/2 at the early stage of blood arrhythmia, so as to regulate the occurrence of arrhythmia. after reviewing the literature, we found that β 1-aa exists in patients with ischemic arrhythmia, coronary heart disease, dilated cardiomyopathy, heart failure, diabetes, dogs with dilated heart disease and hypertensive rats. these β 1-aa targets the second extracellular ring of β 1-ar. moreover, it can produce an agonist like response to spontaneously beating rat cardiomyocytes, inducing ventricular arrhythmias by stimulating β 1-ar and its downstream pathways. this experiment plans to select 60 patients and extract 8ml and 4ml of blood from the elbow vein for centrifugation and serum extraction. β 1-aa will be separated and extracted using a chromatography column; 4ml is used to detect endogenous n/ofq and β 1-aa levels using an elisa kit.

Eligibility criteria:
inclusion criteria:1) inclusion criteria for patients with diabetes: refer to the diagnostic criteria for type 2 diabetes (t2dm) in the chinese guidelines for the prevention and treatment of type 2 diabetes (2017) 2) inclusion criteria for patients with coronary heart disease: patients with clinically diagnosed coronary heart disease according to the 1979 who diagnostic criteria for ischemic heart disease, and exclusion criteria include heart failure, tumor, immune disease and diabetes. - exclusion criteria:exclusion criteria for patients with coronary heart disease: including heart failure, tumor, immune disease and diabetes. -
a study to evaluate the safety and efficacy of baricitinib in the treatment of frontal fibrosing alopecia (ffa)

Conditions: Frontal Fibrosing Alopecia

Summary: the goal of this clinical trial is to evaluate the safety and efficacy of baricitinib in the treatment of frontal fibrosing alopecia (ffa).


Eligibility criteria:
inclusion criteria: * female at least 18 years of age, and able to provide informed consent * females who are post-menopausal defined, as not have menses for at least 12 months without an alternative medical cause and elevated follicle stimulating hormone in the postmenopausal range as measured during screening * have active ffa that has been diagnosed on or prior to screening visit. * have lppai score equal to or greater than 5 at screening. * have evidence of eyebrow loss at baseline * have evidence of hairline recession at baseline * have classic presentation with frontal loss of scalp hair * negative screening for tuberculosis (quantiferon gold, t-spot) within 3 months prior to screening or at the screening visit. * agree not to have a live vaccination during the study the exception is herpes zoster vaccine exclusion criteria: * systemic treatments for ffa within 4 weeks of the baseline visit or 5 half lives whichever one is longer. (ex: finasteride, pioglitazone, hydroxychloroquine, or immunosuppressant medications, such as mycophenolate mofetil). * dutasteride within the last 6 months * have a lppai score less than 5 at screening * immunocompromised and with risk factors concerning to investigator for study participation * previous treatment with an oral jak inhibitor * any condition in the opinion of the investigator which would interfere with the study assessments or procedure * subject is pregnant or breast feeding * surgical intervention including face lifts and micro-blading on the treatment areas * any intervention (facelifts micro blading) that could affect the treatment areas (i.e. scalp and eyebrows) * laser or phototherapy intervention on the treatment areas * have evidence of active tb or latent tb
obstructive sleep apnea treatment on cardiovascular events in patients with acute cardiogenic pulmonary edema: cpap-care study.

Conditions: Obstructive Sleep Apnea; Pulmonary Edema Cardiac Cause

Summary: despite the advances in the treatment of acute cardiogenic pulmonary edema (acpe), the readmissions rates and cardiovascular events remain very high. in this context, it is possible that other potential risk factors may influence the poor prognosis of the acpe. one of these potential candidates is obstructive sleep apnea(osa). this study was designed to evaluate the impact of osa treatment with cpap in consecutive patients with acpe. the primary outcome will be to evaluate the impact of cpap on the recurrence of acpe in the 1-year follow-up.


Eligibility criteria:
inclusion criteria: * hypertensive acute cardiogenic pulmonary edema * moderate to severe osa exclusion criteria: * professional drivers * pregnancy * non-cardiogenic pulmonary edema * terminal cancer
polycystic liver disease registry (uk)

Conditions: Polycystic Liver Disease

Summary: multicentre, observational registry studying the natural course of polycystic liver disease.

the polycystic liver disease (pld) registry (uk) is the uk specific part of an international, multicentre, observational registry. the overall international pld registry is led by radboud university medical center, nijmegan, netherlands. note- please direct any queries about the international registry to the team at radboud university medical center. all patients with polycystic kidney disease (pkd) with pld or patients with isolated (without pkd) polycystic liver disease are eligible for inclusion (\>10 liver cysts). data will be collected prospectively and retrospectively including a specific validated pld questionnaire (pld-q). this registry provides us insight in patient characteristics, risk factors, symptoms, quality of life and treatment strategies in the biggest international pld cohort so far. results of this registry will be published and shared at national and international congresses.

Eligibility criteria:
inclusion criteria: * patients with pld with more than 10 liver cysts * patients with pkd and pld with more than 10 liver cysts exclusion criteria: * patients with pkd or pld with less than 10 liver cysts
heart disease on the mend

Conditions: Coronary Heart Disease; Stroke; Hyperlipidemia; Hypertension

Summary: the primary objective of this study was to evaluate the effectiveness of a multifactor cardiovascular disease (cvd) risk reduction program using team case management in high risk patients who have low family incomes and limited access to medical care. patients were randomized to case management (99) or usual care (49) with baseline, 6-month and 12-month evaluations of cvd risk factors, clinical status and quality of life.

the primary objective of this study was to evaluate the effectiveness of a multifactor cardiovascular disease (cvd) risk reduction program using team case management in high risk patients who have low family incomes and limited access to medical care. patients were randomized to case management (99) or usual care (49) with baseline, 6-month and 12-month evaluations of cvd risk factors, clinical status and quality of life. subjects were primarily recruited from patients being seen in free medical clinics in santa clara county california. primary eligibility was ≥ 35 years of age, one or more cvd risk factors (with or without clinical cvd), low family income, and residing in santa clara county. patients in the case management group were provided counseling services by specially trained registered nurses (rns) and registered dieticians (rds) and assisted in obtaining medications and medical services from programs provided in the county or indigent drug programs provided by selected pharmaceutical companies. protocol driven treatment algorithms based on national practice guidelines were used and use of existing programs and resources were maximized. on average patients in case management were seen by staff 6-9 in the 12 months.

Eligibility criteria:
inclusion criteria: * men and women ≥ 35 years * one or more major risk factors * live in santa clara county * low family income that limits access to medical care exclusion criteria: * under active medical treatment for cancer, cvd or other major medical disorder * reasonable access to health care * under 35 years of age * not a resident of santa clara county

Keywords: risk factor reduction cardiovascular disease prevention
positron emission tomography in monitoring treatment response in women with newly diagnosed breast cancer

Conditions: Adult Women With a New Diagnosis of Invasive Breast Cancer (Have Not Undergone Treatment)

Summary: this study will investigate the sensitivity and specificity of flt-pet/ct in primary breast cancer detection and in the use of flt-pet in monitoring how well a breast tumor respond to treatment. we will compare this technique with other imaging modalities as well as with tissue collection (during a biopsy). we will recruit women with a newly diagnosed invasive breast cancer, who are able to tolerate undergoing a pet/ct (possibly two scans) scan,

our overall goal is to use this clinical trial as a platform to validate fibroblast activation protein (fap) as a biomarker for the tumor microenvironment and to explore the dynamic interaction between proliferating tumor cells and the tumor microenvironment. our long term goal is to develop new drugs that will target the tumor microenvironment as novel therapeutic and chemoprevention strategies.

Eligibility criteria:
inclusion criteria: * breast biopsy positive for an invasive malignancy (core needle, mammatone, or incisional biopsy) * participants must be planning to have surgery at the hospital of the university of pennsylvania * participants must be able to tolerating lying on the table for about an hour * newly diagnosed primary breast cancer, which is classified as being operable (t1-t4) exclusion criteria: * pregnant women * history of severe renal disease * prior history of breast cancer of the study breast within the last five years.
dance and movement therapy in patients with schizophrenia

Conditions: Schizophrenia; Negative Symptoms in Schizophrenia; Disabilities Mental; Dance Therapy

Summary: introduction: schizophrenia is a mental disorder that starts at a young age and progresses with positive (hallucination, delusion) and negative (decreased emotional participation, reluctance) symptoms. while drug therapy in schizophrenia targets positive symptoms; psychotherapies are needed in the treatment of negative symptoms. it is seen that especially art therapies such as occupational and music support recovery and rehabilitation. in addition, it is stated that dance and movement therapy is effective in ensuring social participation of patients. there are a limited number of studies demonstrating the effect of dance and movement therapy on schizophrenia patients. aim: this project was planned to examine the effects of dance and movement therapy techniques to be applied to patients with schizophrenia on patients' negative symptoms and disability. method: in this project, which was planned in a repetitive measure design with a pretest-posttest control group, dance and movement therapy techniques, consisting of 12 sessions in total, will be applied to schizophrenic patients in a community mental health center once a week. negative symptoms and disability levels will be determined before, after and a month after the application. the findings obtained as a result of these three follow-ups will be evaluated. project outputs: reduction of negative symptoms and disability will enable schizophrenic patients to become individuals who can express themselves better in their family and society and have an increased quality of life. it is thought that these gains will increase patients' compliance with treatment, prevent recurrent symptoms and reduce hospitalizations. the results will also constitute a scientific source for the studies to be carried out in the field.


Eligibility criteria:
inclusion criteria: * have been diagnosed with schizophrenia for at least two years * not have been hospitalized in the past 3 months exclusion criteria: * have a therapy/psychoeducation program that they attend regularly * have a known physical or neurological disease * having just started the community mental health center

Keywords: dance and movement therapy
evaluation of cassia fistula + senna alexandrina miller in the chronic functional constipation treatment.

Conditions: Constipation

Summary: primary objective: to evaluate the clinical efficacy of naturetti (capsules) , considering the following criteria: * evacuation frequency during the treatment and follow-up period * consistency of stools during the treatment and follow-up period * global evaluation, regarding increase in frequency of evacuation and shape of stools. secondary objective: * number of days without evacuation * proportion of evacuation with pain * proportion of evacuation with strain * proportion of evacuation with incomplete sensation * proportion of blocked stools * proportion of manual maneuvers to facilitate defecation * proportion of subjects that adhere to the diet recommended * proportion of the patients who have to use rescue medication * level of constipation improvement, according to the patient evaluation * to evaluate clinical tolerability of the study medication by the continuous use * to evaluate the occurrence of adverse events related to the study drug * to identify any drug interaction.


Eligibility criteria:
inclusion criteria: * chronic functional constipation present, diagnosed by rome iii criteria. * present in most evacuations intestinal feces classified as type 1 or 2 by the classification of bristol. * women sexually active and reproductive age, using more than three months effective contraceptive method. * concordance, level of education and consciousness enough to cooperate with the completion of all study procedures. * no contraindication to the use of medication in the study. * availability to attend all the visits of the study evaluation. exclusion criteria: * history or presence of neurological disorders and / or metabolism. * persons with constipation caused by previous surgery. * presence of obstructive lesions in the gastrointestinal tract, including colorectal cancer. * irritable bowel syndrome or inflammatory bowel disease. * multiple sclerosis * parkinson's disease * other abnormalities such as hirschsprung's disease and defecation dissinrgica. * heart disease and / or hypertension. * continuous use of medication such as analgesics, anti-cholinergic (anti-histamines, antispasmodics, antidepressants, anti-psychotics), supplements with iron or aluminum, opiates, anti-hypertensive, calcium channel blockers preganglionic and blockers. * use of any other except the laxative rescue medication during the study. * subjects who do not confirm the diagnosis of icfc during phase i of the study. * pregnant or breast-feeding period. * laboratory tests outside the normal range, or the result is assessed as clinically significant by the investigator. * body mass index (bmi) over 30. * participation in another clinical study within 30 days. * do not fill the correct diary * any condition that in view of the researcher impossible the subject to participate in the study. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
ticagrelor monotherapy in patients treated with new-generation drug-eluting stents for acute coronary syndrome; t-pass trial

Conditions: Coronary Artery Disease, Acute Coronary Syndrome

Summary: we hypothesized that ticagrelor monotherapy might be enough to prevent thromboembolic events without aspirin after pci in patients with acute coronary syndrome(acs). moreover, ticagrelor monotherapy will reduce bleeding risk compared to dapt with aspirin plus ticagrelor. we will also evaluate 1-year safety and efficacy of orsiro stent for patient with acute coronary syndrome. after confirmation of enrollment, patients will be randomized to continue standard treatment (aspirin plus ticagrelor) for 1 year or to stop aspirin after discharge or less than 1 month after pci (ticagrelor monotherapy). randomization will be stratified according to 1) the presence of diabetes and 2) st elevation myocardial infarction (mi). baseline clinical and angiographic characteristics, laboratory findings will be assessed at the time of randomization. all patients will provide informed consent on their own initiative.


Eligibility criteria:
inclusion criteria: 1. patients ≥19 years old 2. patients who received new generation sirolimus-eluting (orsiro® series) stent implantation for treating acs, including acute mi and unstable angina 3. provision of informed consent exclusion criteria: 1. age\> 80 years 2. increased risk of bleeding, anemia, thrombocytopenia 3. a need for oral anticoagulation therapy 4. pregnant women or women with potential childbearing 5. life expectancy \< 1 year
rétrospective evaluation of the performance and the safety of the endoscopic mucosectomy with anchorage

Conditions: Polyps of Colon

Summary: this safe and simple technique without extra cost would allow us to improve r0 resection ratio and so decrease relapses and the time between two different exams


Eligibility criteria:
inclusion criteria: * age over 18 years old * other rectal or colic résections from 10 to 30 mm into the past exclusion criteria: * colitis, crohn disease or ulcerative colitis * intense fibrosis under the lesion
study evaluating sca-136 in subjects with acute exacerbations of schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to determine whether a low dose and a high dose of the study drug sca-136 are effective and safe in the treatment of schizophrenia requiring hospitalization.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of schizophrenia * ability to remain hospitalized for at least first 4 weeks of study * needs hospitalization due to worsening of schizophrenia exclusion criteria: * type 1 or 2 diabetes * previous use of clozapine * serious medical illness other than schizophrenia

Keywords: schizophrenia
electrotherapy in the management of myofascial syndrome

Conditions: Breast Cancer

Summary: myofascial syndrome is defined as "musculoskeletal pain characterized by local and referred pain perceived to be deep and constant, and by the presence of myofascial trigger points in any part of the body" post-breast surgery myofascial syndrome affects up to 44.7% of operated women, mainly on the muscles of the greater shoulder girdle. the repercussions are significant, functional, somatic, psychological and socio-professional affecting the quality of life. the treatments offered may or may not be medicinal. transcutaneous electrical nerve stimulation (tens) is a therapy that uses low voltage electrical current to provide pain relief. a tens unit consists of a battery-powered device that delivers electrical impulses through electrodes placed on the surface of your skin. the electrodes are placed at or near nerves where the pain is located or at trigger points.


Eligibility criteria:
inclusion criteria: * male or female who had first breast cancer surgery, regardless of the type of surgery * age ≥ 18 years * patients with refractory pain with myofascial syndrome, with a numerical scale ≥ 4 * topical treatment for refractory pain completed more than 30 days ago * healthy, non-irritated skin on painful areas to treat * patient with a third party who can attend visits m0 and m2.5 * obtaining the signed written consent of the patient * major patient affiliated to a social security scheme exclusion criteria: * patient who has used tens before on the muscles affected by the myofascial syndrome * post-surgery management of the affected area by a physiotherapist * person with venous thrombosis * contraindications specific to the treatments studied

Keywords: breast cancer surgery myofascial syndrome
aminocamptothecin in treating patients with advanced or recurrent kidney cancer

Conditions: Kidney Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of aminocamptothecin in treating patients with stage iii, stage iv, or recurrent kidney cancer.

objectives: i. determine the response rate, duration of response, and survival of patients with advanced renal cell carcinoma treated with aminocamptothecin colloidal dispersion. ii. determine the nature and degree of toxicity of aminocamptothecin in this patient population. outline: patients receive aminocamptothecin colloidal dispersion intravenously for 120 hours weekly for 2 weeks followed by 1 week of rest. courses are repeated every 3 weeks in the absence of disease progression or dose limiting toxicity. patients are followed every 3 months for the first 2 years, every 6 months for the next 3 years, and yearly thereafter. projected accrual: a total of 10-29 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: histologically proven stage iii, stage iv, or recurrent renal cell carcinoma measurable disease no brain metastases patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: at least 3 months hematopoietic: platelet count at least 100,000/mm3 absolute neutrophil count at least 1500/mm3 hemoglobin at least 9.0 g/dl hepatic: bilirubin no greater than 1.5 mg/dl alt and ast no greater than 2.5 times the institutional normal values renal: creatinine no greater than 1.5 mg/dl other: not pregnant or nursing fertile patients must use effective contraception no uncontrolled systemic infection no other prior or concurrent malignancies except nonmelanoma skin cancer, carcinoma in situ of the cervix, or ductal carcinoma in situ of the breast that have been curatively treated no evidence of delirium, confusion, suicidal ideation, or untreated depression prior concurrent therapy: biologic therapy: at least 30 days since prior cytokines and recovered no more than 1 prior treatment with cytokines (interleukin-2 or interferons) chemotherapy: no prior cytotoxic chemotherapy no prior aminocamptothecin no other concurrent antineoplastic agents endocrine therapy: at least 30 days since prior hormone therapy and recovered no more than 1 prior hormone therapy (tamoxifen or medroxyprogesterone) radiotherapy: prior radiotherapy allowed if indicator lesion and greater than 15% of marrow producing bone have not been irradiated surgery: recovered from prior surgery other: at least 30 days since other investigational agents no concurrent investigational agents

Keywords: stage iii renal cell cancer stage iv renal cell cancer recurrent renal cell cancer